As previously reported, Leerink initiated coverage of Contineum (CTNM) with an Outperform rating and $20 price target. Idiopathic pulmonary fibrosis might no longer be a drug development graveyard, the firm says. There have been two Phase 3 successes in the past year, and Bristol Myers (BMY) is advancing an LPA1R antagonist in a large Phase 3 program with data expected in the second half of 2026. Leerink likes Contineum for their fast-follower approach to LPA1R, with the thesis that Bristol Myers’ admilparant will be first-in-class while Contineum’s PIPE-791 will emerge as the best-in-class program with improved pharmacology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Contineum initiated with an Outperform at Leerink
- Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b Results
- Buy Rating for Contineum Therapeutics’ PIPE-791: Promising Phase 1b Results and Competitive Edge
- Contineum announces topline data from PIPE-791 trial
- Contineum Therapeutics Announces Positive Phase 1b Trial Results